Amytrx Therapeutics
Manufacturing · Tennessee, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
102 Woodmont Blvd Ste 237, Nashville, Te...Phone Number
(615) 383-6166Website
www.amytrx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Amytrx Therapeutics
Amytrx is a clinical-stage biopharmaceutical company advancing the next generation of new anti-inflammatory peptide therapies for patients suffering from chronic inflammatory diseases. The company is a group of dedicated scientific, medical, and business professionals all deeply committed to positively transforming the health and lives of patients. The company's breakthrough therapeutic platform, AMTX-100, is a first-in-class anti-inflammatory peptide bioengineered from human protein sequences that modulate the immune system by a natural process, reducing pathogenesis in a range of conditions. This completely novel approach to restoring immune balance harnesses significant potential for safer and more effective treatments across a range of diseases where medical need remains. The company's business strategy includes exploring collaborative opportunities with pharmaceutical and biotechnology partners, as well as clinical and research organizations, to advance new or complementary therapRead more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Amytrx Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Amytrx Therapeutics launches new products
Amytrx Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Amytrx Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Amytrx Therapeutics
Earning: See what the market has to say on Amytrx Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Amytrx Therapeutics has new funding data
Check if Amytrx Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Click to see if Amytrx Therapeutics had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Amytrx Therapeutics
Find 3 more new buyers
Compare Similar Companies to Amytrx Therapeutics
Compare insights from companies similar to Amytrx Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Amytrx Therapeutics
<$5M
1-10
Private
$18M
2014
N/A
<$5M
1-10
Private
$37.5M
2011
Company Profile Activity
Activity Insights
Amytrx Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Amytrx Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Amytrx Therapeutics.
Amytrx Therapeutics financials insights
Gather financial insights about Amytrx Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Other Financing Round
$18M
Amytrx Therapeutics Tech Stack
A closer look at the technologies used by Amytrx Therapeutics
Most Recent Scoops
Executive Move
Board of Directors
Executive Move
Board of Directors
Funding
Funding
Amytrx Therapeutics News & Media
Amytrx Therapeutics' AMTX-100 Phase 1 Clinical Trial Data Presented at Revolutionizing Atopic Dermatitis Conference
NASHVILLE, Tenn., July 25, 2023 /PRNewswire/ -- Amytrx Therapeutics, an emerging pharmaceutical company specializing in innovative anti-inflammatory therapies, has announced that their abstract from the Revolutionizing Atopic Dermatitis (RAD) Conference has been published in the British...Amytrx Therapeutics Announces Open Enrollment for Phase 2b Clinical Trial of AMTX-100 CF3, a Promising Anti-Inflammatory Peptide Therapeutic for Atopic Dermatitis
NASHVILLE, June 28, 2023 /PRNewswire/ -- Amytrx Therapeutics, an emerging pharmaceutical company specializing in innovative anti-inflammatory therapies, is pleased to announce the open enrollment for its highly anticipated Phase 2b clinical trial of a topical formulation of AMTX-100 CF3,...Amytrx Therapeutics Partners With AmbioPharm to Expand the Potential of Its Breakthrough Leukocyte-Targeting Anti-Inflammatory Human Peptides
NASHVILLE, Tenn. & NORTH AUGUSTA, S.C.--(BUSINESS WIRE)-- #antiinflammatory--Amytrx Therapeutics announces an expansion of its partnership with AmbioPharm to manufacture its lead anti-inflammatory peptide, AMTX-100.Amytrx Therapeutic's AMTX-100 CF3 Moves to Phase II Clinical Trial for Atopic Dermatitis
Amarex Clinical Research, LLC Guides Its Client to Phase II of FDA Trials GERMANTOWN, Md., June 9, 2022 /PRNewswire/ -- Amytrx and Amarex Clinical Research, LLC, an NSF company, today announced they are initiating the Phase II clinical trial on atopic dermatitis (AD) using Amytrx's...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Amytrx Therapeutics
Sign Up For FreeTo access detailed company insights
Amytrx is a clinical-stage biopharmaceutical company advancing the next generation of new anti-inflammatory peptide therapies for patients suffering from chronic inflammatory diseases. The company is a group of dedicated scientific, medical, and business professionals all deeply committed to positively transforming the health and lives of patients.... Read More
